skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays

Abstract

Identifying useful markers of cancer can be problematic due to limited amounts of sample. Some samples such as nipple aspirate fluid (NAF) or early-stage tumors are inherently small. Other samples such as serum are collected in larger volumes but archives of these samples are very valuable and only small amounts of each sample may be available for a single study. Also, given the diverse nature of cancer and the inherent variability in individual protein levels, it seems likely that the best approach to screen for cancer will be to determine the profile of a battery of proteins. As a result, a major challenge in identifying protein markers of disease is the ability to screen many proteins using very small amounts of sample. In this review, we outline some technological advances in proteomics that greatly advance this capability. Specifically, we propose a strategy for identifying markers of breast cancer in NAF that utilizes mass spectrometry (MS) to simultaneously screen hundreds or thousands of proteins in each sample. The best potential markers identified by the MS analysis can then be extensively characterized using an ELISA microarray assay. Because the microarray analysis is quantitative and large numbers of samples can be efficiently analyzed,more » this approach offers the ability to rapidly assess a battery of selected proteins in a manner that is directly relevant to traditional clinical assays.« less

Authors:
; ; ;
Publication Date:
Research Org.:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org.:
US Department of Energy (US)
OSTI Identifier:
15010737
Report Number(s):
PNNL-SA-42179
820201000; TRN: US200501%%396
DOE Contract Number:  
AC05-76RL01830
Resource Type:
Journal Article
Journal Name:
Disease Markers
Additional Journal Information:
Journal Volume: 20; Journal Issue: 3; Other Information: PBD: 1 Oct 2004
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; DISEASES; ENZYME IMMUNOASSAY; MAMMARY GLANDS; MASS SPECTROSCOPY; NEOPLASMS; PROTEINS; SCREENS

Citation Formats

Zangar, Richard C, Varnum, Susan M, Covington, Chandice Y, and Smith, Richard D. A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays. United States: N. p., 2004. Web. doi:10.1155/2004/754640.
Zangar, Richard C, Varnum, Susan M, Covington, Chandice Y, & Smith, Richard D. A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays. United States. https://doi.org/10.1155/2004/754640
Zangar, Richard C, Varnum, Susan M, Covington, Chandice Y, and Smith, Richard D. 2004. "A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays". United States. https://doi.org/10.1155/2004/754640.
@article{osti_15010737,
title = {A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays},
author = {Zangar, Richard C and Varnum, Susan M and Covington, Chandice Y and Smith, Richard D},
abstractNote = {Identifying useful markers of cancer can be problematic due to limited amounts of sample. Some samples such as nipple aspirate fluid (NAF) or early-stage tumors are inherently small. Other samples such as serum are collected in larger volumes but archives of these samples are very valuable and only small amounts of each sample may be available for a single study. Also, given the diverse nature of cancer and the inherent variability in individual protein levels, it seems likely that the best approach to screen for cancer will be to determine the profile of a battery of proteins. As a result, a major challenge in identifying protein markers of disease is the ability to screen many proteins using very small amounts of sample. In this review, we outline some technological advances in proteomics that greatly advance this capability. Specifically, we propose a strategy for identifying markers of breast cancer in NAF that utilizes mass spectrometry (MS) to simultaneously screen hundreds or thousands of proteins in each sample. The best potential markers identified by the MS analysis can then be extensively characterized using an ELISA microarray assay. Because the microarray analysis is quantitative and large numbers of samples can be efficiently analyzed, this approach offers the ability to rapidly assess a battery of selected proteins in a manner that is directly relevant to traditional clinical assays.},
doi = {10.1155/2004/754640},
url = {https://www.osti.gov/biblio/15010737}, journal = {Disease Markers},
number = 3,
volume = 20,
place = {United States},
year = {Fri Oct 01 00:00:00 EDT 2004},
month = {Fri Oct 01 00:00:00 EDT 2004}
}